Flamel Technologies SA's ( NASDAQ : FLML ) business model is to blend high-value internally developed products with its leading drug delivery capabilities. The company markets Bloxiverz™ (neostigmine methylsulfate) in the USA and manufactures Micropump-based microparticles under FDA-audited GMP guidelines for Coreg CR® (carvedilol phosphate), marketed in the USA by GlaxoSmithKline. The Company has a proprietary pipeline of niche specialty pharmaceutical products, while its drug delivery platforms are focused on the goal of developing safer, more efficacious formulations of drugs to address unmet medical needs. Its pipeline includes chemical and biological drugs formulated with its Micropump® (and its applications to the development of liquid formulations LiquiTime® and of abuse-deterrent formulations Trigger Lock™) and Medusa™ proprietary drug delivery platforms. Several Medusa-based products have been successfully tested in clinical trials. The Company is headquartered in Lyon, France and has operations in St. Louis, Missouri, USA, and manufacturing facilities in Pessac, France.
Looking for a particular Flamel Technologies employee's phone or email?
Flamel Technologies Questions
The Flamel Technologies annual revenue was $173 million in 2026.
Flamel Technologies is based in Venissieux, Auvergne-Rhone-Alpes.
The NAICS codes for Flamel Technologies are [54171, 54, 541, 541711, 5417].
The SIC codes for Flamel Technologies are [283, 28].
